Celera will acquire all of the assets of Atria for approximately $33 million in cash. Atria has a line of human leukocyte antigen (HLA) testing products that are used for identifying potential donors in the matching process for bone marrow transplantation. "This acquisition gives us direct access to this important niche market area of tissue typing in transplantation and the bone marrow registry markets," said Kathy Ordonez, president of Celera.
- see the release [0]Â for more on the deal
Related Articles:
Schering licenses Celera autoimmune program. Report [0]
Celera moves to cut staff. Report [0]